ReviewLife (Basel, Switzerland)2026
Better Discrimination, Unchanged Practice: Are Machine Learning Models Ready to Replace Established Risk Scores in Cardiac Surgery? A Narrative Review.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preoperative risk stratification underpins consent, treatment selection, and quality benchmarking in cardiac surgery, a task served for two decades by regression-derived scores such as the European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) and the Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM), together with procedure-specific tools. A rapidly expanding literature reports that machine learning (ML) models achieve higher discrimination than these scores, yet established scores remain the instruments actually used at the bedside. This narrative review examines that paradox. Drawing on studies emphasized between 2023 and 2026, we argue that the reported advantage of ML is real but modest. This advantage is driven primarily by improved discrimination, while key measures of clinical value, including calibration, net benefit, and external or temporal validation, are infrequently reported. We organize the evidence around a four-lens appraisal (discrimination, calibration, clinical utility, and generalizability) and show that most cardiac surgery ML studies focus only on discrimination. We then consider why superior discrimination has not changed practice and outline the evidence needed for an ML-based risk model to justify replacing an established scoring system. The current literature supports a measured conclusion: ML is a discrimination upgrade in search of clinical proof.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.